Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: a population-based study.
Anti-neoplastic agents
Drug interaction
Emergency department
Geriatrics
Inappropriate polypharmacy
Potentially inappropriate medication
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
07
06
2020
accepted:
08
09
2020
pubmed:
11
10
2020
medline:
18
5
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
We aimed to investigate the prevalence and predicting factors of inappropriate polypharmacy including potentially inappropriate medications (PIMs) and drug-drug interactions (DDIs) and their associations with emergency department (ED) visits in older Korean patients receiving anti-neoplastic therapy. We identified older patients receiving anti-neoplastic therapy in 2016 from the National Health Claims database. We investigated the prevalence of inappropriate polypharmacy comprising PIMs and DDIs in geriatric patients according to the 2019 American Geriatrics Society Beers Criteria Inappropriate polypharmacy, its subtype PIMs, geriatric, and chemotherapeutic DDIs were observed in 85.4%, 80.4%, 17.3%, and 37.9% of the 21,956 patients receiving anti-neoplastic therapy, respectively. After adjusting for confounding factors, the presence of inappropriate polypharmacy (adjusted odds ratio (aOR) 2.15, 95% confidence interval (CI) 1.97-2.35), 2 or more PIMs (aOR 1.85, 95% CI 1.68-2.02), 2 or more chemotherapeutic DDIs (aOR 2.88, 95% CI 2.54-3.28), and geriatric DDIs (aOR 1.61, 95% CI 1.43-1.80) increased the likelihood of ED visits during anti-neoplastic therapy. This nationwide study showed that inappropriate polypharmacy was prevalent and increased the risk of ED visits in older patients receiving anti-neoplastic therapy. Study findings suggested a need to implement deprescribing strategies in this population.
Identifiants
pubmed: 33037903
doi: 10.1007/s00520-020-05759-5
pii: 10.1007/s00520-020-05759-5
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3025-3034Subventions
Organisme : Seoul National University
ID : Creative-Pioneering Researchers Program
Références
Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, Soerjomataram I (2019) Global cancer incidence in older adults, 2012 and 2035: A population-based study. Int J Cancer 144(1):49–58. https://doi.org/10.1002/ijc.31664
doi: 10.1002/ijc.31664
pubmed: 29978474
LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP (2015) Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 16:e333–e341. https://doi.org/10.1016/S1470-2045(15)00080-7
doi: 10.1016/S1470-2045(15)00080-7
pubmed: 26149885
Maggiore RJ, Gross CP, Hurria A (2010) Polypharmacy in older adults with cancer. Oncologist 15(5):507–522. https://doi.org/10.1634/theoncologist.2009-0290
doi: 10.1634/theoncologist.2009-0290
pubmed: 20418534
pmcid: 3227983
Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK (2014) Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 62(12):2261–2272. https://doi.org/10.1111/jgs.13153
doi: 10.1111/jgs.13153
pubmed: 25516023
pmcid: 4270076
Cadogan CA, Ryan C, Hughes CM (2016) Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf 39(2):109–116. https://doi.org/10.1007/s40264-015-0378-5
doi: 10.1007/s40264-015-0378-5
pubmed: 26692396
World Health Organization (2019) Medication safety in polypharmacy: technical report, World Health Organization
Alkan A, Yaşar A, Karcı E, Köksoy EB, Ürün M, Şenler FÇ, Ürün Y, Tuncay G, Ergün H, Akbulut H (2017) Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer 25(1):229–236. https://doi.org/10.1007/s00520-016-3409-6
doi: 10.1007/s00520-016-3409-6
pubmed: 27619388
Reis CM, Dos Santos AG, de Jesus SP, Reis AMM (2017) Factors associated with the use of potentially inappropriate medications by older adults with cancer. J Geriatric Oncol 8(4):303–307. https://doi.org/10.1016/j.jgo.2017.05.003
doi: 10.1016/j.jgo.2017.05.003
Van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071–1078. https://doi.org/10.1038/bjc.2013.48
doi: 10.1038/bjc.2013.48
pubmed: 23412102
pmcid: 3619066
Kim SH, Suh Y, Ah YM, Jun K, Lee JY (2019) Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study. Support Care Cancer. https://doi.org/10.1007/s00520-019-05204-2
Park JW, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY (2016) Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. J Cancer Res Clin Oncol 142(5):1031–1040. https://doi.org/10.1007/s00432-015-2108-x
doi: 10.1007/s00432-015-2108-x
pubmed: 26744323
Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Kim JH (2020) Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy. Oncologist 25(3):e502–e511. https://doi.org/10.1634/theoncologist.2019-0085
doi: 10.1634/theoncologist.2019-0085
pubmed: 32162799
Leger DY, Moreau S, Signol N, Fargeas JB, Picat MA, Penot A, Abraham J, Laroche ML, Bordessoule D (2018) Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients. J Geriatric Oncol 9(1):60–67. https://doi.org/10.1016/j.jgo.2017.07.015
doi: 10.1016/j.jgo.2017.07.015
Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM (2016) Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatric Oncol 7(5):346–353. https://doi.org/10.1016/j.jgo.2016.07.010
doi: 10.1016/j.jgo.2016.07.010
Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S, Castillo D, Sharma M, Holmes HM, Nightingale G, Juba KM, Mohile SG (2020) Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist 25(1):e94–e108. https://doi.org/10.1634/theoncologist.2019-0406
doi: 10.1634/theoncologist.2019-0406
pubmed: 31570516
Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, Owusu C, Klepin HD, Lichtman SM, Gajra A, Ramani R, Katheria V, Zavala L, Hurria A, Cancer, Aging Research G (2014) Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc 62(8):1505–1512. https://doi.org/10.1111/jgs.12942
doi: 10.1111/jgs.12942
pubmed: 25041361
pmcid: 4134360
Sharma M, Holmes HM, Mehta HB, Chen H, Aparasu RR, Shih YT, Giordano SH, Johnson ML (2019) The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 125(7):1155–1162. https://doi.org/10.1002/cncr.31917
doi: 10.1002/cncr.31917
pubmed: 30605231
pmcid: 6420393
Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, Dombrowski R, DuBeau CE, Pezzullo L, Epplin JJ, Flanagan N, Morden E, Hanlon J, Hollmann P, Laird R, Linnebur S, Sandhu S (2019) American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67(4):674–694. https://doi.org/10.1111/jgs.15767
doi: 10.1111/jgs.15767
Seulki An J-YL, Young-Mi A (2020) Evaluation of information consistency of clinically significant drug interactions in tyrosine kinase inhibitors. Korean J Clin Pharm 30(1):44–50. https://doi.org/10.24304/kjcp.2020.30.1.44
doi: 10.24304/kjcp.2020.30.1.44
Storms H, Marquet K, Aertgeerts B, Claes N (2017) Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: a systematic review. Eur J Gen Pract 23(1):69–77. https://doi.org/10.1080/13814788.2017.1288211
doi: 10.1080/13814788.2017.1288211
pubmed: 28271916
pmcid: 5774291
Morin L, Laroche ML, Texier G, Johnell K (2016) Prevalence of potentially inappropriate medication use in older adults living in nursing homes: a systematic review. J Am Med Dir Assoc 17(9):862.e861–862.e869. https://doi.org/10.1016/j.jamda.2016.06.011
doi: 10.1016/j.jamda.2016.06.011
Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC Jr, Giordano SH (2018) Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 124(14):3000–3007. https://doi.org/10.1002/cncr.31403
doi: 10.1002/cncr.31403
pubmed: 29689595
pmcid: 6033638
Chiang LY, Liu J, Flood KL, Carroll MB, Piccirillo JF, Stark S, Wang A, Wildes TM (2015) Geriatric assessment as predictors of hospital readmission in older adults with cancer. J Geriatric Oncol 6(4):254–261. https://doi.org/10.1016/j.jgo.2015.04.003
doi: 10.1016/j.jgo.2015.04.003
Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S (2013) Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013(3):CD004310. https://doi.org/10.1002/14651858.CD004310.pub3
doi: 10.1002/14651858.CD004310.pub3
pmcid: 6418472
Hanlon JT, Boudreau RM, Roumani YF, Newman AB, Ruby CM, Wright RM, Hilmer SN, Shorr RI, Bauer DC, Simonsick EM, Studenski SA (2009) Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci 64(4):492–498. https://doi.org/10.1093/gerona/gln043
doi: 10.1093/gerona/gln043
pubmed: 19196642
Gerretsen P, Pollock BG (2011) Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf 10(5):751–765. https://doi.org/10.1517/14740338.2011.579899
doi: 10.1517/14740338.2011.579899
pubmed: 21635190
Jun K, Ah YM, Hwang S, Chung JE, Lee JY (2020) Prevalence of anticholinergic burden and risk factors amongst the older population: analysis of insurance claims data of Korean patients. Int J Clin Pharm 42(2):453–461. https://doi.org/10.1007/s11096-020-01010-7
doi: 10.1007/s11096-020-01010-7
pubmed: 32281075
Wawruch M, Zikavska M, Wsolova L, Jezova D, Fialova D, Kunzo M, Kuzelova M, Lassanova M, Kruty P, Kriska M (2006) Perception of potentially inappropriate medication in elderly patients by Slovak physicians. Pharmacoepidemiol Drug Saf 15(11):829–834. https://doi.org/10.1002/pds.1290
doi: 10.1002/pds.1290
pubmed: 16927435